Compare Prudential Financial Inc (PRU) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs Twist Bioscience Corp — how do they compare? Prudential Financial Inc trades at $111.8 (market cap $39.17B), while Twist Bioscience Corp trades at $154.45 (market cap $10.08B). The key difference: Prudential Financial Inc is far larger — about 3.9× Twist Bioscience Corp's market cap, and Prudential Financial Inc pays a 4.93% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential Financial Inc for 145 Days and Twist Bioscience Corp for 27 Days on average.
| PRU | TWST | |
|---|---|---|
Market Cap | $39.17B | $10.08B |
Volume | 1,436,917 | 4,229,037 |
Sector | Financials | Health |
52-Week High | $125.13 | $205.00 |
52-Week Low | $92.00 | $25.45 |
Typical Hold Time | 145 Days | 27 Days |
Enterprise Value | $67.95B | $10.01B |
Dividend Yield | 4.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $112.36, down 1.04% with a bearish technical outlook. The stock shows attractive valuation metrics including a P/E of 10.19 and P/S of 0.61, while recent earnings beat expectations in two of the last three quarters. The company is executing a strategic overhaul including a $3 billion capital rotation plan and emerging market exits, while benefiting from higher interest rates that boost investment income.
PRU presents a value opportunity with strong fundamentals but faces near-term technical pressure. The 67.57% analyst hold rating reflects cautious optimism, with the current price above the $105.67 consensus target. Key risks include execution of strategic initiatives and annuity market competition, while higher rates provide tailwinds for insurance operations.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
